Previously, we reported pathologic FGF23-FGFR4 signaling might contribute to excess inflammatory mediators (Singh et al., 2016), and we now followed up on the FGF23 inflammatory role in clinically relevant CKD models in vivo. This evidence concerns the gene FGF23 and chronic kidney disease.